Exam III Asthma COPD Flashcards

(36 cards)

1
Q

Asthma VS COPD

A

Asthma

  • Allergen based irritation
  • Smooth muscle thickening-> bronchoconstriction
  • Episodic SOB, wheeze, cough, chest tightness
  • Often reversible lung fxn w/ meds

COPD

  • Inflammation-based irritation
  • Cellular damage by external irritants
  • Chronic cough, sputum production, Dyspnea on Exertion
  • Often irreversible lung fxn w/ meds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment approaches for Asthma

A

Short-acting B agonists (SABA)

Long-acting B agonists (LABA)

Inhaled corticosteroids (ICS) – oral too

Mast cell stabilizers

Leukotriene antagonists

Methylxanthine derivatives

Immunotherapy

Long acting antimuscarinics (LAMA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Treatment approaches for COPD

A

Smoking cessation

Short-acting B agonists (SABA)

Long-acting B agonists (LABA)

Short-acting antimuscarinics (SAMA)

Long-acting antimuscarinics (LAMA)

Inhaled corticosteroids (ICS) – oral too

Methylxanthine derivatives

Phosphodiesterase 4 (PDE-4) inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Notes on Delivery systems

A

Aerosolized delivery systems preferred

-+: small particles size, delivered directly to leading to reduced systemic exposure, doses usually lower, usually quicker onset

–: requires proper technique for effective therapy, expensive, variability in devices that require different techniques

Multiple delivery systems including metered dose inhaler (MDI), dry powder inhaler (DPI), soft mist inhaler, nebulizer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Aerosolized delivery systems - Metered dose inhaler (MDI)

A

Advantages

  • Small, compact, portable, Easy to use (<1 minute)
  • Can be used with spacer
  • No drug prep

Disadvantages

  • Needs proper technique / coordination with breath (requires breath hold)
  • Expensive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Aerosolized delivery systems – Dry powder inhaler (DPI)

A

Advantages

  • Small, compact, portable
  • Easy to use (<1 minute)
  • Usually cheaper vs MDI
  • Less coordination needed

Disadvantages

  • PT must prepare the dose
  • Requires fast, deep inhalation (requires breath hold)
  • Moisture sensitive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Aerosolized delivery systems – Soft Mist inhaler

A

Advantages

  • Compact, portable
  • Multi-dose device
  • High lung deposition
  • Does not contain propellants

Disadvantages

  • Complicated process for first dose
  • Slow moving mist
  • Cannot use a spacer
  • Expensive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Aerosolized delivery systems – Nebulizer

A

Advantages

  • Minimal technique required
  • PT is not required to Hold breath

Disadvantage

  • Expensive, requires dose prep
  • Bulky (not portable)
  • Administration time 5-15 minutes
  • Needs a power source
  • Cleaning needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Considerations for device selection

A

PT related factors

-Age, physical and cognitive abilities

PT preference

Availability of the drug

-Combination products

Convenience

-Portability, maintenance, cleaning

Cost / reimbursement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bronchodilators

A

SABA

LABA

Muscarinic antagonists

Methylxanthine derivatives

PDE-4 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Short-Acting B2 Agonists (SABA)

A

MOA: Stimulate adenylyl cyclase at B2. Inc cAMp. Dilation

Selective for B2

Drug of choice for Acute Asthma Attacks and exercise-induced Asthma

  • Onset 5 minutes
  • Duration 3-4 Hours

Route: Inhalation

Well tolerated for PRN use

ADR:

  • Mouth Irritation and Cough
  • At high doses

–Skeletal muscle tremor

– Tachycardia/palpations

–Arrhythmia

–Tolerance with excessive use

—Decreased responsiveness and decrease in number of B receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SABA Agents

A

Albuterol

-Racemic mixture of (S)-albuterol and (R)-albuterol

–(R)-albuterol (levalbuterol) is therapeutically active

–(S)-albuterol is clinically inert but has unwanted side effects

Levalbuterol

  • Developed to minimize side effects
  • In acute asthma (&COPD) attacks, no sig Diff in efficacy
  • No Diff in HR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Long Acting B2 Agonists (LABA)

A

MOA: Same as SABA

  • Slower onset (~30 min)
  • Longer duration (12-24 Hrs)

Not for rescue therapy

Cannot be used as MONOTHERAPY

-Ok in COPD

ADEs same as SABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

LABA Agents

A

Long-acting

  • Salmeterol
  • Formoterol

Ultra-long acting

  • Indacaterol
  • Olodaterol
  • Vilanterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antimuscarinics

A

MoA: Competitively block muscarinic receptors (M1, M2, M3) and the effects of ACh in airway-> Prevent vasoconstriction mediated by vagal discharge

No effects on Chronic inflammation

Bronchodilation effect last longer than B agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Antimuscarinic ADEs

A

Minimally absorbed, generally well tolerated

Potential for:

  • Dry mouth, eyes
  • Bitter, metallic taste
  • Constipation
  • Urinary retention

No tremors or arrhythmias

17
Q

Antimuscarinic Agents

A

Ipratropium

Tiotropium

Aclidinium

Umeclidinium

Glycopyrolate

18
Q

Methylxanthine derivative

A

Theophylline – oral

MoA: (1) Non-selectively inhibits phosphodiesterase (PDE)-> increases cAMP-> broncodilation (2) Block adenosine receptors-> bronchodilation

Duration: ~12 Hrs

Requires high concentration

Narrow therapeutic index

19
Q

Theophylline

A

Metabolized via CYP450, 1A2 enzyme system

-Many DDIs – febuxostat, bupropion, carbamazepine, macrolide antibiotics, etc.

Clearance mediated by age, smoking status, and other drugs

Requires monitor

-Therapeutic range 10-20 mcg/mL

–Levels correlate with efficacy

Smoking will reduce drug levels as smoking is a 1A2 inducer.

20
Q

Theophylline ADEs

A

GI distress (enhanced gastric acid secretion)

Tremor

Insomnia

In overdose, severe nausea and vomiting, hypotension, agitation, arrhythmias, cardiac arrest, seizures

21
Q

PDE-4 inhibitors

A

Roflumilast – oral

MoA: Not fully elucidates; selectively inhibits PDE-4-> increases cAMP-> bronchodilation

Used for severe or very severe COPD

-should be given in combination with at least 1 other long-acting bronchodilator for COPD

Given by mouth once daily

-Duration of action > 10-20 Hrs

22
Q

Roflumilast ADE/DDI

A

Partially metabolized by CYP450 3A4

-DDIs with rifampin, phenobarbital, phenytoin, carbamazepine

ADEs:

  • Diarrhea, nausea, vomiting, abdominal pain, HA, dyspepsia
  • Psychiatric events
  • Weight loss
23
Q

Corticosteroids

A

MoA: Binds glucocorticoid receptor to:

  • Inhibit inflammatory cell migration/activation
  • Inhibit cytokine and mediator release
  • Up regulate B2 receptors
  • Inhibit IgE synthesis

Drug of choice for persistent asthma

-Prophylaxis

May take 4-6 weeks for effect

Multiple dosing

Do not abruptly D/C – Taper

24
Q

Corticosteroid (inhaled) ADEs

A

Inhaled

Thrush (oral candidiasis)

-Counsel PTs to rinse mouth after use

Dysphonia

Sore throat

Cough

25
**Corticosteroid (oral/IV) ADEs**
Adrenal suppression Cushing Syndrome Growth retardation Osteoporosis Glucose intolerance Infection risk Mood changes Weight gain Edema
26
**Corticosteroid agents**
Inhaled - Beclomethasone - Budesonide - Fluticasone propionate - Fluticasone furoate - Mometasone - Flunisolide - Ciclesonide Oral/IV - Prednisone - Prednisolone - Methylprednisolone - Hydrocortisone
27
**Corticosteroids in kids**
Potential growth stunting in children Still preferred DOC (drug of choice) in children
28
**Leukotriene antagonists – Lipoxygenase inhibitor**
**Zileuton – Oral** **MoA: Inhibits actions of 5-lipoxygenase to inhibit the synthesis of Leukotrienes** **ADEs:** HA Insomnia Somnolence GI Upset Hepatotoxicity -Do not administer if LFTs >3x ULN -Females > 65 Yrs of age and those with preexisting LFT elevations are highest-risk -> monitor!
29
Leukotriene Receptor Antagonists
Montelukast - Oral Zafirlukast - Oral MOA: Competitively block actions of Leukotrienes at the LTD receptor Can be used for asthma, allergic symptoms, exercise-induced bronchospasm, urticaria
30
Leukotriene receptor antagonists
**DDIs**: Zafirlukast + warfarin -\> may increase risk of bleed **ADEs**: Generally well tolerated HA Hepatoxicity (Zafirlukast) Neuropsychiatric events -Abnormal Dreams, hostility, aggression, suicidality, agitation, hallucinations, etc. --2008: Reports to FDA MedWatch --2009: Labeling change on all leukotrienes
31
Mast cell stabilizers
**Indicated for mild asthma cases** -Not used much in clin practice Not for rescue use Require multiple daily doses Clin improvement may take 2-6 weeks Well tolerated -Mild throat irritation, cough abnormal taste No DDIs
32
Immunotherapy - Anti IgE agents
Omalizumab MOA: **Monoclonal IgE antibody** -\> inhibits binding of IgE to surface of mast cells & basophils -\> **inhibits release of inflammatory mediators** Indicated for **allergic asthma not relieved with corticosteroid therapy** -Must have evidence of allergic sensitization Dose based on IgE levels and body weight **-Sub Q injection** every 2-4 weeks
33
Omalizumab - ADEs/DDIs
Indicated for \> 12 Y/O Clin improvement delayed - Takes up to 12 weeks ADEs: - Injection site RXN (45%) - Anaphylaxis -\> 1.5-2 hours post-dose (watch for RXN) - Arthralgia, HA - Pharyngitis, sinusitis - **Malignancies**? DDI-None
34
IL-5 Antagonists
Mepolizumab Reslizumab
35
IL-5 MOA
Humanized IL-5 monoclonal antibody antagonist to **reduce** the amount of **circulating eosinophils** Used for the **maintenance of severe asthma** for PTs who continue to have attacks despite therapy Admin: **SubQ (mepolizumab)** **IV (reslizumab)** q4w by HCP
36
IL-5 ADEs
Not recommended monotherapy -Must be \> 18 Y/O with eosinophilic phenotype ADEs: **-Injection site RXN** **-HA** **-Hypersensitivity RXNs** -\>Anaphylaxis **-Malignancy?** **-Muscle/Face pain**